Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb turns laboratory science into prescription drugs, getting paid by healthcare providers and insurers worldwide.
Is Bristol-Myers Squibb Company a good stock for a UK beginner?
The honest version: Bristol-Myers Squibb turns laboratory science into prescription drugs, getting paid by healthcare providers and insurers worldwide.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Successful development of multiple blockbuster therapies transforming healthcare.
Failure to innovate, leading to a shrinking product lineup.
What does Bristol-Myers Squibb Company do?
This pharmaceutical giant relies on hospitals, pharmacies, and insurance systems purchasing its specialised medicines to generate revenue. It constantly pours money into research to find the next big medical breakthrough. What matters most is how well its newer treatments make up for older blockbusters losing their exclusive patent protections.
On our factor screen it looks strongest on momentum and value, and weakest on growth.
- ✓Pays a dividend - about 3.9% a year
- ✓Growing - revenue up about 6% over the year
- ✓Very profitable - turns about 19% of sales into profit
- !Carries a lot of debt - roughly 2.0x its equity
- ✓Strong return on shareholder money (ROE 47%)
- Momentum screens high (88/100)
- High gross margin showing strong pricing power on specialised medicines
- Solid dividend income stream for shareholders
- Calmer share price movement relative to the broader market
- Loss of patent protection allowing cheaper generic alternatives to enter the market
- Changes in government healthcare policies and drug pricing pressures
- Clinical trial failures wasting substantial research spending
What do Bristol-Myers Squibb Company's numbers mean?
How much money does Bristol-Myers Squibb Company make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Bristol-Myers Squibb Company pay a dividend?
Yes - Bristol-Myers Squibb Company currently pays a dividend of about 3.9% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Bristol-Myers Squibb Company report earnings, and how did recent quarters go?
Bristol-Myers Squibb Company is next scheduled to report on about 2026-10-29 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $1.60 | $2.04 | Beat +28% |
| 2026-04-30 | $1.42 | $1.58 | Beat +11% |
| 2026-02-05 | $1.20 | $1.26 | Beat +5% |
| 2025-10-30 | $1.52 | $1.63 | Beat +8% |
| 2025-07-31 | $1.10 | $1.46 | Beat +33% |
| 2025-04-24 | $1.50 | $1.80 | Beat +20% |
Across the last 6 quarters here, Bristol-Myers Squibb Company came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Bristol-Myers Squibb Company?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Bristol-Myers Squibb Company?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High gross margin showing strong pricing power on specialised medicines
- Solid dividend income stream for shareholders
- Calmer share price movement relative to the broader market
- Heavily reliant on ongoing scientific research success
- Revenue growth is modest at present
- Significant reliance on a few key treatments
- Loss of patent protection allowing cheaper generic alternatives to enter the market
- Changes in government healthcare policies and drug pricing pressures
- Clinical trial failures wasting substantial research spending
The write-up's own warning lights — if these start happening, the case above changes.
- Major regulatory rejections for core pipeline drugs
- A sudden acceleration or collapse in patent litigation outcomes
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.